



Call for Abstracts Frequently Asked Questions (FAQs)

Q: What is the character/word count?

A: 3,000 characters including spaces.

Q: Does the character/word count include title, author names, affiliations, etc.?

A: No, just the abstract body is counted toward this count.

Q: During submission if you chose oral presentation opposed to poster and your abstract is not selected for oral will it still be considered for poster presentation?

A: Yes, if you indicate you are open to having your abstract considered for poster presentation.

Q: Are tables allowed? Is there a limit to how many you can include in your abstract? Do they count towards the character limit?

A: Tables are not allowed as part of the abstract submission.

Q: Are figures allowed? Is there a limit to how many you can include in your abstract? Do they count towards the character limit?

A: Figures are not allowed as part of the abstract submission.

Q: Is there an author limit?

A: Yes, 25 co-authors.

Q: Is there a title character limit?

A: Yes, 200 characters.

Q: Are encore abstracts permitted?

A: Yes, although new data is encouraged, and scoring will depend on expanding on what was presented at other meetings.

Q: Where are accepted abstracts published?

A: Abstracts will be published in a supplement of the *Clinical Lymphoma, Myeloma, & Leukemia Journal*.

Q: Are disclosures required?

A: Yes, this information will be collected upon abstract acceptance.

Q: Are Trials in Progress (TiP) allowed?

A: Yes, as long as tentative, data-based conclusions are stated in the abstract. Please type in the abstract body at the very beginning of the text “Trial in Progress.”

Q: Is it possible to change the presenter to a different author after the May 30 deadline (e.g., if there is a schedule conflict or a change in travel plans for the original presenter)?

A: Yes, send an email to imsabstracts@spargoinc.com.

Q: Is a COI form required for each author as part of the submission process?

A: No, COI/disclosure forms will only be required for oral abstracts, upon acceptance from the presenting author.

Q: If I submit an abstract as a certain submission type, will it be accepted as that type?

A: The Program Committee may accept the abstract as a different type than what was originally submitted. This is usually due to the number of abstracts submitted in each category and how the information will best be presented.

Q: How do I submit an abstract?

A: Abstracts are submitted online through the abstract submission site. Abstracts must be submitted by the deadline of May 30, 2023 at 11:59 pm EDT. Late-breaking abstracts will be accepted from June 28-July 28, 2023 at 11:59 EDT.

Q: How many presenting authors may I have?

A: One presenter.

Q: What responsibilities does the Presenting Author have?

A: The presenting author is responsible for the following:

- Presenting the abstract, if accepted.
- Assuring that all appropriate financial and non-financial relationship disclosures have been made. Disclosure of financial relationships with commercial entities is required for the presenting author and his/her spouse and institution.
- Announcing the disclosures before the presentation of the abstract.
- Logging in to the abstract site to RSVP acceptance of the presentation and review the presentation guidelines, if accepted.
- Presenters must register for the IMS meeting and are responsible for all registration fees and personal expenses related to the meeting.

Q: What information do I need about my other authors?

A: You will need the full name, email address, institution, and location (city, state and country) for all authors.

Q: May I submit more than one abstract?

A: Yes, there is no limit to the number of abstracts that you may submit. Authors who submit multiple abstracts should be prepared to make arrangements for alternative presenters to attend in case more than one abstract is accepted.

Q: Will I receive a confirmation email once I submit an abstract?

A: Yes, you will receive a confirmation email once the submission has been finalized. It will be sent from imsabstracts@spargoinc.com.

Q: When will I receive notification if my abstract was accepted or declined for presentation?

A: Abstract notifications will be emailed by Late June/Early July 2023. Late-breaking abstract notifications will be issued by Mid-August 2023.

Q: How are the abstracts reviewed?

A: All abstracts will be blinded and peer reviewed by the Program Committee and invited reviewers. The reviewers assign scores based on topic, relevance, innovation, quality of material, interest to IMS attendees and available space. Abstracts are selected based on their aggregate score and slotted into sessions accordingly. Note that the Program Committee may change the abstract type, if accepted.

Q: Will IMS accept late abstracts?

A: Abstracts must be submitted by the deadline of May 30, 2023, at 11:59 p.m. EDT. The IMS organizers will not accept late abstracts. Late-Breaking Abstracts are open from June 28-July 28, 2023 at 11:59 pm EDT.

Q: Can I make changes to the abstract after it has been finalized?

A: You may make changes to the abstract before the submission deadline. You will be required to re-finalize the abstract. Only finalized abstracts will be reviewed.

Q: May I add a presenter after my abstract is accepted?

A: You may add a presenter after an abstract is accepted by emailing imsabstracts@spargoinc.com. The new presenter must be an existing co-author on the abstract. Depending upon the date of the notification, a new presenter may not appear in the printed program. However, the presenter update will be reflected in the mobile app and website.

Q: How long do I have to withdraw my abstract?

A: Abstracts submitted by the May 30, 2023, deadline may be withdrawn up to July 3, 2023 11:59 pm EDT. If it is after that time, please email imsabstracts@spargoinc.com.

Q: Are there any discounts for presenters to attend the IMS Annual Meeting?

A: No. Presenters pay the same registration fees as other attendees.

Q: Who retains the copyright for accepted abstracts?

A: IMS holds the copyright for all accepted abstracts.